# James Posada

> James Posada is a scientist, biotech executive, and company founder whose career has moved from foundational work on MAP kinase signaling to pharmaceutical R&D, business development, and the leadership of Resolve Therapeutics. He founded Resolve in 2010 and now leads its work on therapies designed around cell-free nucleic acids, while remaining active as an inventor, author, and scientific collaborator.

- **Role:** Founder and Chief Executive Officer at Resolve Therapeutics, LLC
- **Organizations:** Resolve Therapeutics, LLC, Posada & Associates, Inc., GlycoFi, Inc., Eli Lilly and Company, University of Vermont College of Medicine, Fred Hutchinson Cancer Center
- **Education:** Ph.D. in Pharmacology, University of Vermont College of Medicine, NIH postdoctoral fellowship, Fred Hutchinson Cancer Research Center
- **Known for:** Contributed to foundational work identifying ERK2/MAP kinase and its upstream activation pathway., Established an NIH-funded academic research laboratory at the University of Vermont., Led discovery programs and R&D scientists within Eli Lilly's therapeutic-proteins organization.

## Career timeline

- **Early career** — Completed an NIH postdoctoral fellowship at Fred Hutchinson Cancer Research Center and contributed to foundational MAP kinase research.
- **1990s** — Served as a tenure-track assistant professor at the University of Vermont College of Medicine and established an NIH-funded cell-signaling laboratory.
- **Before 2006** — Worked on the management team of Eli Lilly's therapeutic-proteins R&D organization, with responsibility for scientists and discovery programs.
- **Before 2006** — Served as senior vice president of business and market development, later described by Resolve as chief business officer, at GlycoFi.
- **2006** — Helped structure GlycoFi collaborations with Eli Lilly and Merck and participated in the process that led to GlycoFi's acquisition by Merck.
- **2006** — Founded Posada & Associates, a life-sciences consulting firm for early-stage biotech companies.
- **2010** — Co-founded Resolve Therapeutics and became chief executive officer.
- **2012** — Resolve announced a $5.8 million financing round to advance its lead investigational program.
- **2016** — Co-authored research connecting blood-borne RNA with disease activity and interferon-stimulated gene expression.
- **2020** — Co-authored a randomized clinical-trial paper in Arthritis & Rheumatology.
- **2024** — Was named as an inventor on U.S. Patent 12,077,790 for optimized binuclease fusions and methods; also co-authored a Phase 2 trial publication.
- **2025** — Resolve began a Duke School of Medicine collaboration studying cell-free RNA in polytrauma and Posada presented the company's platform at CNAPS in Hong Kong.
- **2026** — Resolve announced a collaboration with Institut Pasteur de Montevideo and B4-RNA using REJOIN-seq to analyze cell-free RNA.

## Achievements

- Contributed to foundational work identifying ERK2/MAP kinase and its upstream activation pathway.
- Established an NIH-funded academic research laboratory at the University of Vermont.
- Led discovery programs and R&D scientists within Eli Lilly's therapeutic-proteins organization.
- Structured major GlycoFi collaborations with Eli Lilly and Merck and helped lead the process culminating in Merck's 2006 acquisition of GlycoFi.
- Founded Resolve Therapeutics in 2010 and has led it through financing, research publications, patents, clinical programs, and institutional collaborations.
- Listed by ORCID with 25 works; Resolve states he has authored more than 30 peer-reviewed publications and is an inventor on more than 50 patents.

## Latest updates

- **2026-04** — Resolve Therapeutics announced a collaboration with Institut Pasteur de Montevideo and B4-RNA to use REJOIN-seq in the study of cell-free RNA.
- **2026-04** — Listed as a presenting-company speaker at the ChinaBio Partnering Forum in Shanghai.
- **2025-12** — Presented Resolve's work on cell-free nucleic acids as drug targets at the CNAPS symposium in Hong Kong.
- **2025-05** — Resolve and Duke School of Medicine initiated an observational cell-free RNA research collaboration in polytrauma.
- **2024-09** — Named as an inventor on U.S. Patent 12,077,790 for optimized binuclease fusions and methods.

## Links

- Website: https://www.resolvetherapeutics.com
- LinkedIn: https://www.linkedin.com/in/james-posada-ph-d-88b67713
- Twitter/X: https://twitter.com/Jimposada
- Facebook: https://facebook.com/ResolveBio

---

Profile page: https://yespress.io/james-posada
Published by YesPress — https://yespress.io
Last updated: 2026-08-27